drugset / Trial / NCT01268566
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TOVETUMAB | Monoclonal antibody | 25 mg/kg | Intravenous |